Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes
Conditions
Interventions
VPI-2690B low dose
VPI-2690B medium dose
+2 more
Locations
34
United States
Birmingham, Alabama, United States
Little Rock, Arkansas, United States
La Mesa, California, United States
Riverside, California, United States
Sacramento, California, United States
Tustin, California, United States
Start Date
September 1, 2014
Primary Completion Date
March 1, 2017
Completion Date
March 1, 2017
Last Updated
March 28, 2017
NCT06954090
NCT07476248
NCT02010242
NCT06332378
NCT05487755
NCT06326034
Lead Sponsor
Vascular Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions